semaglutide injection fda approval Approves Oral as First GLP-1 Pill for Weight Loss Novo Nordisk secures FDA approval

When GLP-1 binds to its receptor, it increased insulin secretion inhibition of glucagon release reduced glucose production by the liver Insulin is a hormone that lowers blood sugar levels by helping the bodys cells use glucose, or sugar, for energy

In its decision, the regulator told Citius it would need to incorporate enhanced product testing and additional controls that were agreed to during the market application review

Clinical Evidence: REDEFINE Program# REDEFINE 1 (Without Type 2 Diabetes)# 3,417 adults randomized to CagriSema (n=2,108), semaglutide alone (n=302), cagrilintide alone (n=302), or placebo (n=705) for 68 weeks

Demand is running ahead of clinic menus generally, a gap we quantify in what peptide patients actually ask for